GlassScriptPhysician profile
Ajay Thakur
NPI 1770571846
$1,422.75
in general payments reported to CMS, 2019-2025
24 companies · $234 in 2025
The $234 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $136 · 2021: $340 · 2022: $233 · 2023: $154 · 2024: $178 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $566.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $195.74 | 2020-2021 | |
| Medtronic, INC. | $184.39 | 2021-2025 | Symplicity G3 |
| Abbott Laboratories | $144.98 | 2020-2023 | Cardiomems |
| Vital Connect, INC | $128.50 | 2022 | |
| Kestra Medical Technology Services, INC. | $95.83 | 2024-2025 | Assure Wcd |
| Abiomed | $94.98 | 2024 | Impella |
| Medtronic Vascular, INC. | $83.63 | 2020 | |
| Amgen INC. | $71.26 | 2019-2023 | Repatha |
| Atricure, INC. | $58.45 | 2024-2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Novartis Pharmaceuticals Corporation | $36.57 | 2019 | |
| Pfizer INC. | $34.44 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $31.08 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.77 | 2022 | |
| Alnylam Pharmaceuticals INC. | $27.15 | 2025 | Amvuttra |
| Actelion Pharmaceuticals US, INC. | $26.50 | 2025 | Uptravi |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $26.32 | 2025 | Farxiga |
| Bridgebio Pharma, INC. | $26.19 | 2025 | Attruby |
| Merck Sharp & Dohme LLC | $21.37 | 2024 | Verquvo |
| Impulse Dynamics (USA) INC. | $21.05 | 2022 | |
| Nevro Corp. | $19.65 | 2022 | |
| Janssen Pharmaceuticals, INC | $19.54 | 2019 | |
| Amarin Pharma, INC. | $18.83 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.53 | 2021 | |
| Bardy Diagnostics, INC. | $10.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajay Thakur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.